<DOC>
	<DOCNO>NCT01787578</DOCNO>
	<brief_summary>The purpose study assess safety , tolerance , pharmacokinetics , pharmacodynamics sobetirome , selective thyroid hormone analog , adult male X-ALD patient .</brief_summary>
	<brief_title>Safety Pharmacodynamic Study Sobetirome X-Linked Adrenoleukodystrophy ( X-ALD )</brief_title>
	<detailed_description>Subjects screen visit within 6 week prior Baseline visit . At Baseline visit blood drawn establish baseline value plasma red blood cell ( RBC ) long chain fatty acid ( VLCFA ; C22 , C24 , C26 ) . Subjects receive oral dose 50 mcg sobetirome daily 14 day begin Day 1 . Subjects keep clinic Day 1 16 hour follow initial dose sobetirome repeat blood sample pharmacokinetic analysis . Subjects return clinic day 7 , 15 , 21 28 blood collection VLCFA measurement . On day 15 , safety assessment , subject receive increase dose 100 mcg dose continued daily Day 28 . Subjects continue return clinic weekly blood urine collection safety assessment . Subjects return clinic day 42 End Study visit involve final measurement VLCFA blood urine safety labs check reversibility . Safety labs include serum chemistry , free fatty acid profile , hematology , urinalysis , thyroid function . Subjects monitor ECGs , vital sign , physical exam assessment adverse event .</detailed_description>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<criteria>male 1865 year old XALD diagnosis either elevate VLCFAs DNA test must sign informed consent agree complete require clinic visit . female gender abnormal laboratory test result ( except VLCFA ) screen visit history coronary artery disease use triiodothyronine therapy abnormal thyroid function test screen visit untreated adrenal insufficiency currently take Lorenzo 's Oil VLCFA lower agent participation investigational drug study within 30 day</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>X-linked adrenoleukodystrophy</keyword>
	<keyword>adrenomyeloneuropathy</keyword>
	<keyword>sobetirome</keyword>
	<keyword>thyroid</keyword>
	<keyword>thyromimetic</keyword>
</DOC>